Compare REFR & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFR | PLUR |
|---|---|---|
| Founded | 1965 | 2001 |
| Country | United States | Israel |
| Employees | N/A | 142 |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 36.9M |
| IPO Year | 1995 | 2001 |
| Metric | REFR | PLUR |
|---|---|---|
| Price | $1.05 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 36.2K | 11.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,488,642.00 | $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $0.93 | $2.82 |
| 52 Week High | $2.70 | $7.13 |
| Indicator | REFR | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 34.30 | 57.25 |
| Support Level | $0.98 | $3.43 |
| Resistance Level | $1.28 | $3.85 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 10.45 | 69.59 |
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.